-
UPDATE: Oppenheimer Upgrades Biogen Idec from Perform to Outperform
Thursday, August 18, 2011 - 8:59am | 97Oppenheimer has published a research report on Biogen Idec Inc (NASDAQ: BIIB). In the report, Oppenheimer wrote, "BIIB has declined significantly on recent market weakness, despite no change in the company's fundamentals. We believe BG-12 will become a blockbuster oral MS therapy, based our...
-
Oppenheimer Upgrades Biogen Idec To Outperform, $100 PT
Thursday, August 18, 2011 - 8:44am | 25Oppenheimer has upgraded Biogen Idec (NASDAQ: BIIB) from Perform to Outperform and has established a $100 price target.
-
Oppenheimer Upgrading Biogen Idec
Thursday, August 18, 2011 - 8:41am | 158Oppenheimer & Co. is out with a research report on Biogen Idec Inc. (NASDAQ: BIIB) and is upgrading shares to Outperform and it has a $109 price target on shares. In a note to clients, Oppenheimer & Co. writes, "BIIB has declined significantly on recent market weakness, despite no change...
-
Bank of America Merrill Lynch Maintains Neutral on Regeneron Pharmaceuticals
Thursday, August 18, 2011 - 8:38am | 76Bank of America Merrill Lynch is out with its report today on Regeneron Pharmaceuticals (NASDAQ: REGN), maintaining Neutral. In its report, Bank of America Merrill Lynch writes, "We rate REGN shares Neutral. Our DCF-derived PO of $58 is based on risk-adjusted revenue projections of the key...
-
NPS Pharmaceuticals Submits Chemistry, Manufacturing and Controls Section of New Drug Application for GATTEX
Thursday, August 18, 2011 - 8:37am | 102NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today announced that it has submitted the chemistry, manufacturing and controls section of its new drug application for GATTEX to the U.S. Food and Drug Administration. GATTEX is a novel, recombinant analog of human glucagon-like peptide 2 that the company...
-
News Summary for August 18, 2011
Thursday, August 18, 2011 - 7:46am | 685This is your Benzinga news summary and traders' outlook for Thursday, August 18, 2011, covering headlines from overnight and Thursday's pre-market session. Today in domestic pre-market trading, U.S. equity futures are trading lower. Morgan Stanley lowered its global growth targets for both 2011...
-
Celgene Announces Additional $2 Billion Share Repurchase Authorization
Thursday, August 18, 2011 - 7:34am | 123Celgene Corporation (NASDAQ: CELG) announced the Company's Board of Directors has authorized the repurchase of up to an additional $2 billion of the Company's common stock. This open-ended program is effective immediately. Purchases may be made in the open market or in privately negotiated...
-
Merck and ARIAD Announce European Medicines Agency Accepts Marketing Authorization Application for Ridaforolimus
Thursday, August 18, 2011 - 7:32am | 169Merck (NYSE: MRK) and ARIAD Pharmaceuticals, Inc., (NASDAQ: ARIA), today announced that the European Medicines Agency has completed its administrative validation process for the regulatory application for ridaforolimus, an investigational oral mTOR inhibitor developed for the treatment of...
-
Randomized Study Comparing Cell Therapeutics' OPAXIO and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
Thursday, August 18, 2011 - 6:51am | 115Cell Therapeutics, Inc (NASDAQ: CTIC) announced that enrollment has opened for a randomized phase II clinical study comparing the combination of OPAXIO (paclitaxel poliglumex, PPX) and radiation to the combination of temozolomide and RT for patients with newly diagnosed glioblastoma, a high-grade...
-
Gentium Withdraws New Drug Application for Defibrotide
Wednesday, August 17, 2011 - 4:15pm | 183Gentium S.p.A. (Nasdaq: GENT) today announced that it has voluntarily withdrawn the New Drug Application (NDA) for Defibrotide following recent correspondence from the United States Food and Drug Administration (FDA) identifying numerous "Refuse to File" issues regarding the Company's NDA...
-
August 16 Safety Monitoring Committee Meeting for Nymox Pivotal Phase 3 NX-1207 Trials Indicates Favorable Safety Profile
Wednesday, August 17, 2011 - 10:16am | 200Nymox Pharmaceutical Corporation (Nasdaq: NYMX) provided an update today on the Company's Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of August 16, 2011 was favorable and indicated no significant...
-
Hemispherx Biopharma Submits for Regulatory Approval of Alferon(R) in Argentina
Wednesday, August 17, 2011 - 10:00am | 247Hemispherx Biopharma, Inc. (NYSE: HEB) today announced its authorized agent GP Pharm Argentina has submitted to the ANMAT (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica) regulatory agency responsible for the national administration of drugs, foods and medical technology for...
-
Morning Market Movers
Wednesday, August 17, 2011 - 9:53am | 111China Yida Holding Co (NASDAQ: CNYD) climbed 31.58% to $4.50 at 9:45 am. CNYD shares have dropped 66.21% over the past 52 weeks, while the S&P 500 index has gained 9.17% in the same period. MarketAxess Holdings Inc (NASDAQ: MKTX) shares advanced 21.79% to $29.29. MKTX is considering a sale,...
-
Morning Market Movers
Wednesday, August 17, 2011 - 9:48am | 111China Yida Holding Co (NASDAQ: CNYD) climbed 31.58% to $4.50 at 9:45 am. CNYD shares have dropped 66.21% over the past 52 weeks, while the S&P 500 index has gained 9.17% in the same period. MarketAxess Holdings Inc (NASDAQ: MKTX) shares advanced 21.79% to $29.29. MKTX is considering a sale,...
-
CEL-SCI Receives Key Chinese Patent for Its Investigational Cancer Therapy Multikine
Wednesday, August 17, 2011 - 9:35am | 56CEL-SCI Corporation (NYSE: CVM) today announced that the Chinese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine. The patent, Chinese patent number ZL200480025403.6, is titled, “A Method of Pre-Sensitizing Cancer Prior to Treatment with Radiation...